Targeted trial aims to help underrepresented patients with serious transplant complication
NCT ID NCT05567406
Summary
This study aimed to test the safety and effectiveness of an oral drug called belumosudil for people with chronic graft-versus-host disease (cGVHD), a serious complication after a stem cell or bone marrow transplant. It specifically focused on recruiting Black, African American, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander participants whose cGVHD had not improved after at least two other treatments. The trial was designed to see if the drug could control the disease and improve symptoms, but the study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.